ClinicalTrials.gg
CompletedNCT00560417Updated Jan 13, 2011Results posted

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide

A Phase 3 interventional study of Insulin Lispro Protamine Suspension and Insulin Glargine in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 52 sites in 2 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2011-01-13.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
339
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 2.

Enrollment
12th of 36
339 · median 127
Started
2007
with 4 others
Phase 3
9 of 36
none open now
Registered
8th of 36
by date
Lead sponsor
26 of 36
Eli Lilly and Company

Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment, is one of 5 that started in 2007, is one of 9 in phase 3, and was the 8th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2 diabetes.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have type 2 diabetes
  • Must be at least 18 years of age and less than 75 years of age
  • Must be taking exenatide 10 micrograms twice a day (BID) for at least 3 months
  • Must be taking one of the following oral diabetes medication regimens for at least 3 months: (1) metformin (2) metformin + sulfonylurea (3) metformin + thiazolidinedione (TZD). Doses must be at or above the following: Metformin--1500 mg/day, Sulfonylurea--1/2 the maximum daily dose according to the product label, TZD--30 mg/day pioglitazone
  • Must have a greater than or equal to 7.0% and less than or equal to 10.0%

Exclusion criteria

Exclusion Criteria:

  • Must not have used insulin on a regular basis during the past 2 years
  • Must not have taken any glucose-lowering medications not included in the inclusion criteria in the past 3 months
  • Must not have had more than one episode of severe hypoglycemia in the past 6 months
  • Must not have hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease
  • Must not be pregnant or intend to get pregnant during the course of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
339 participants (actual)

Study arms

  • Active comparator
    ILPS

    Insulin Lispro Protamine Suspension (ILPS)

    Drug: Insulin Lispro Protamine Suspension

  • Active comparator
    Glargine

    Insulin Glargine

    Drug: Insulin Glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])

    Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline sulfonylurea (SU) Group.

    Time frame: Baseline, Endpoint (LOCF) up to 24 weeks

Secondary outcomes

  1. Actual Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)

    Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline SU Group.

    Time frame: 24 weeks, Endpoint (LOCF) up to 24 weeks

  2. Change From Baseline in Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)

    Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline SU Group.

    Time frame: Baseline, 24 Weeks, Endpoint (LOCF) up to 24 weeks

  3. Percentage of Participants With Hemoglobin A1C Less Than 7.0% and Hemoglobin A1C Less Than or Equal to 6.5%

    Time frame: Weeks 12, 18, 24 and Endpoint (LOCF) up to 24 weeks

  4. 7-Point Self-Monitored Blood Glucose (SMBG) Profiles at Baseline and Endpoint (LOCF)

    SMBG at morning pre-meal, morning post-prandial, midday pre-meal, midday post-prandial, evening pre-meal, evening postprandial, 0300 hours. Post-prandial glucose is measured 2 hours after the start of the meal.

    Time frame: Baseline, Endpoint (LOCF) up to 24 weeks

  5. Glycemic Variability at Baseline and Endpoint (LOCF)

    Glycemic variability was defined as the standard deviation (SD) of a participant's intra-day 7-point, self-monitored, blood glucose. Mean SD was calculated based on the SD for each participant in the study.

    Time frame: Baseline, Endpoint (LOCF) up to 24 weeks

  6. Incidence of Self-reported Hypoglycemic Episodes (All, Non-Nocturnal, Nocturnal, and Severe)

    Overall:any time after randomization.Episode:any time patient experienced sign/symptom associated with hypoglycemia, or had blood glucose level ≤70 mg/dL. Non-nocturnal:any episode that occurred between waking and bedtime. Nocturnal:any episode that occurred between bedtime and waking.Severe:episode with symptoms consistent with neuroglycopenia in which patient requires assistance,and is associated with:blood glucose value \<50 mg/dL or prompt recovery after oral carbohydrate, glucagon, or intravenous glucose.Incidence(%)=(Number of patients experiencing episodes/number of patients in arm)\*100.

    Time frame: Baseline to Endpoint (LOCF) up to 24 weeks

  7. Rate of All, Non-Nocturnal, and Nocturnal Self-Reported Hypoglycemic Episodes (Adjusted for One Year)

    Rate of self-reported hypoglycemic episodes, all, non-nocturnal, and nocturnal, at Endpoint (LOCF) and overall. Rate is reported as episodes/participant/365 days. Episode = any time participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia or has a blood glucose level of ≤70 mg/dL, even if it was not associated with signs, symptoms, or treatment. Overall=any time during the post-randomization visits within the study period. Nocturnal=Any episode that occurs between bedtime and waking. Non-Nocturnal=Any episode that occurs between waking and bedtime.

    Time frame: Baseline to Endpoint (LOCF) up to 24 weeks

  8. Actual Body Weight at Baseline and Endpoint (LOCF)

    Time frame: Baseline, Endpoint (LOCF) up to 24 weeks

  9. Change From Baseline in Body Weight at Endpoint (LOCF)

    Time frame: Baseline, Endpoint (LOCF) up to 24 weeks

  10. Total Daily Insulin Dose at Endpoint (LOCF)

    Time frame: Endpoint (LOCF) up to 24 weeks

07

Results

Posted Dec 14, 2010

Participant flow

Participant flow — Overall Study
MilestoneILPSGlargine
Started171168
Intention to treat (itt) population170167
Completed154151
Not completed1717
Withdrew: Adverse event32
Withdrew: Entry criteria not met10
Withdrew: Lost to follow-up01
Withdrew: Physician decision26
Withdrew: Protocol violation65
Withdrew: Sponsor decision20
Withdrew: Withdrawal by subject33

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])

Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline sulfonylurea (SU) Group.

Time frame:
Baseline, Endpoint (LOCF) up to 24 weeks
Reported as:
Least squares mean · percent of glycosylated hemoglobin
Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])
percent of glycosylated hemoglobinILPSGlargine
Baseline8.48 ± 0.048.47 ± 0.04
Endpoint (LOCF) Change-1.21 ± 0.07-1.43 ± 0.07
Statistical analysis
  • ILPS vs Glargine · ANCOVA · Mean difference (final values): 0.22 · 95% CI 0.06 to 0.38Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group.
SecondaryActual Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)

Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline SU Group.

Time frame:
24 weeks, Endpoint (LOCF) up to 24 weeks
Reported as:
Least squares mean · percent of glycosylated hemoglobin
Actual Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)
percent of glycosylated hemoglobinILPSGlargine
24 weeks6.94 ± 0.076.70 ± 0.06
Endpoint (LOCF)7.00 ± 0.076.78 ± 0.07
Statistical analysis
  • ILPS vs Glargine · ANCOVA · p = 0.003 (p-value is for 24 weeks.) · Mean difference (final values): 0.24 · 95% CI 0.08 to 0.39Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
  • ILPS vs Glargine · ANCOVA · p = 0.008 (p-value is for Endpoint (LOCF)) · Mean difference (final values): 0.22 · 95% CI 0.06 to 0.38Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
SecondaryChange From Baseline in Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)

Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline SU Group.

Time frame:
Baseline, 24 Weeks, Endpoint (LOCF) up to 24 weeks
Reported as:
Least squares mean · percent of glycosylated hemoglobin
Change From Baseline in Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)
percent of glycosylated hemoglobinILPSGlargine
Baseline8.48 ± 0.048.47 ± 0.04
24 Weeks Change-1.25 ± 0.07-1.49 ± 0.06
Endpoint (LOCF) Change-1.21 ± 0.07-1.43 ± 0.07
Statistical analysis
  • ILPS vs Glargine · ANCOVA · p = 0.003 (p-value is for 24 Weeks change.) · Mean difference (final values): 0.24 · 95% CI 0.08 to 0.39Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
  • ILPS vs Glargine · ANCOVA · p = 0.008 (p-value is for Endpoint (LOCF) Change.) · Mean difference (final values): 0.22 · 95% CI 0.06 to 0.38
SecondaryPercentage of Participants With Hemoglobin A1C Less Than 7.0% and Hemoglobin A1C Less Than or Equal to 6.5%
Time frame:
Weeks 12, 18, 24 and Endpoint (LOCF) up to 24 weeks
Reported as:
Number · percent of participants
Percentage of Participants With Hemoglobin A1C Less Than 7.0% and Hemoglobin A1C Less Than or Equal to 6.5%
percent of participantsILPSGlargine
Week 12: HbA1c <7.0%46.950.7
Week 12: HbA1c <=6.5%24.828.7
Week 18: HbA1c <7.0%54.869.1
Week 18: HbA1c <=6.5%30.837.6
Week 24: HbA1c <7.0%55.463.4
Week 24: HbA1c <=6.5%29.739.9
Endpoint (LOCF): HbA1c <7.0%53.761.7
Endpoint (LOCF): HbA1c <=6.5%28.438.9
Statistical analysis
  • ILPS vs Glargine · Fisher Exact · p = 0.561 (p-value is for Week 12: HbA1c \<7.0%)
  • ILPS vs Glargine · Fisher Exact · p = 0.511 (p-value is for Week 12: HbA1c \<=6.5%)
  • ILPS vs Glargine · Fisher Exact · p = 0.012 (p-value is for Week 18: HbA1c \<7.0%)
  • ILPS vs Glargine · Fisher Exact · p = 0.269 (p-value is for Week 18: HbA1c \<=6.5%)
  • ILPS vs Glargine · Fisher Exact · p = 0.161 (p-value is for Week 24: HbA1c \<7.0%)
  • ILPS vs Glargine · Fisher Exact · p = 0.071 (p-value is for Week 24: HbA1c \<=6.5%)
  • ILPS vs Glargine · Fisher Exact · p = 0.177 (p-value is for Endpoint (LOCF): HbA1c \<7.0%)
  • ILPS vs Glargine · Fisher Exact · p = 0.060 (p-value is for Endpoint (LOCF): HbA1c \<=6.5%)
Secondary7-Point Self-Monitored Blood Glucose (SMBG) Profiles at Baseline and Endpoint (LOCF)

SMBG at morning pre-meal, morning post-prandial, midday pre-meal, midday post-prandial, evening pre-meal, evening postprandial, 0300 hours. Post-prandial glucose is measured 2 hours after the start of the meal.

Time frame:
Baseline, Endpoint (LOCF) up to 24 weeks
Reported as:
Mean · milligrams per deciliter (mg/dL)
7-Point Self-Monitored Blood Glucose (SMBG) Profiles at Baseline and Endpoint (LOCF)
milligrams per deciliter (mg/dL)ILPSGlargine
Baseline Morning Pre-Meal175.41 ± 39.54180.86 ± 38.95
Baseline Morning Postprandial195.31 ± 54.65190.84 ± 54.95
Baseline Midday Pre-Meal165.18 ± 43.51166.34 ± 47.64
Baseline Midday Postprandial193.22 ± 46.95200.25 ± 54.64
Baseline Evening Pre-Meal173.33 ± 44.60175.14 ± 43.35
Baseline Evening Postprandial189.00 ± 49.62184.92 ± 49.42
Baseline 0300 Hours170.51 ± 43.44172.00 ± 39.10
Baseline Daily Mean 7-Point Blood Glucose180.19 ± 36.95180.72 ± 38.17
Baseline Daily Mean Pre-Meal170.60 ± 36.06172.66 ± 38.60
Baseline Daily Mean Postprandial192.37 ± 41.48191.27 ± 46.11
Endpoint Morning Pre-Meal129.63 ± 31.58127.01 ± 29.08
Endpoint Morning Postprandial152.32 ± 44.81137.39 ± 36.65
Endpoint Midday Pre-Meal132.84 ± 36.63129.71 ± 34.34
Endpoint Midday Postprandial161.77 ± 42.46155.26 ± 37.86
Endpoint Evening Pre-Meal146.03 ± 37.93135.93 ± 33.79
Endpoint Evening Postprandial159.14 ± 45.35144.25 ± 34.17
Endpoint 0300 Hours123.96 ± 35.45127.53 ± 30.90
Endpoint Daily Mean 7-Point Blood Glucose143.06 ± 30.00136.17 ± 25.65
Endpoint Daily Mean Pre-Meal135.51 ± 30.39129.32 ± 26.54
Endpoint Daily Mean Postprandial158.10 ± 36.81146.12 ± 30.37
Statistical analysis
  • ILPS vs Glargine · ANCOVA · p = 0.179 (p-value is for Endpoint Morning Pre-Meal.) · Mean difference (final values): 4.28 · 95% CI -1.97 to 10.53Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
  • ILPS vs Glargine · ANCOVA · p = <0.001 (p-value is for Endpoint Morning Postprandial.) · Mean difference (final values): 13.96 · 95% CI 5.72 to 22.19Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
  • ILPS vs Glargine · ANCOVA · p = 0.325 (p-value is for Endpoint Midday Pre-Meal.) · Mean difference (final values): 3.80 · 95% CI -3.79 to 11.39Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
  • ILPS vs Glargine · ANCOVA · p = 0.051 (p-value is for Endpoint Midday Postprandial.) · Mean difference (final values): 8.73 · 95% CI -0.04 to 17.50Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
  • ILPS vs Glargine · ANCOVA · p = 0.003 (p-value is for Endpoint Evening Pre-Meal.) · Mean difference (final values): 10.92 · 95% CI 3.66 to 18.19Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
  • ILPS vs Glargine · ANCOVA · p = 0.002 (p-value is for Endpoint Evening Postprandial.) · Mean difference (final values): 14.19 · 95% CI 5.44 to 22.94Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
  • ILPS vs Glargine · ANCOVA · p = 0.415 (p-value is for Endpoint 0300 Hours.) · Mean difference (final values): -3.03 · 95% CI -10.35 to 4.28Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
  • ILPS vs Glargine · ANCOVA · p = 0.015 (p-value is for Endpoint Daily Mean 7-Point Blood Glucose.) · Mean difference (final values): 7.39 · 95% CI 1.46 to 13.32Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
  • ILPS vs Glargine · ANCOVA · p = 0.021 (p-value is for Endpoint Daily Mean Pre-Meal.) · Mean difference (final values): 7.12 · 95% CI 1.10 to 13.14Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
  • ILPS vs Glargine · ANCOVA · p = <0.001 (p-value is for Endpoint Daily Mean Postprandial.) · Mean difference (final values): 11.97 · 95% CI 5.01 to 18.93Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group
SecondaryGlycemic Variability at Baseline and Endpoint (LOCF)

Glycemic variability was defined as the standard deviation (SD) of a participant's intra-day 7-point, self-monitored, blood glucose. Mean SD was calculated based on the SD for each participant in the study.

Time frame:
Baseline, Endpoint (LOCF) up to 24 weeks
Reported as:
Mean · mg/dL
Glycemic Variability at Baseline and Endpoint (LOCF)
mg/dLILPSGlargine
Baseline41.15 ± 13.6939.02 ± 13.52
Endpoint36.78 ± 16.0230.96 ± 13.24
Statistical analysis
  • ILPS vs Glargine · ANOVA · p = 0.131 (p-value is for Baseline.) · Mean difference (final values): 2.27 · 95% CI -0.68 to 5.22Variable = Treatment + Baseline HbA1c Group + Baseline SU Group
  • ILPS vs Glargine · ANOVA · p = <0.001 (p-value is for Endpoint.) · Mean difference (final values): 5.99 · 95% CI 2.82 to 9.16Variable = Treatment + Baseline HbA1c Group + Baseline SU Group
SecondaryIncidence of Self-reported Hypoglycemic Episodes (All, Non-Nocturnal, Nocturnal, and Severe)

Overall:any time after randomization.Episode:any time patient experienced sign/symptom associated with hypoglycemia, or had blood glucose level ≤70 mg/dL. Non-nocturnal:any episode that occurred between waking and bedtime. Nocturnal:any episode that occurred between bedtime and waking.Severe:episode with symptoms consistent with neuroglycopenia in which patient requires assistance,and is associated with:blood glucose value \<50 mg/dL or prompt recovery after oral carbohydrate, glucagon, or intravenous glucose.Incidence(%)=(Number of patients experiencing episodes/number of patients in arm)\*100.

Time frame:
Baseline to Endpoint (LOCF) up to 24 weeks
Reported as:
Number · percentage of participants
Incidence of Self-reported Hypoglycemic Episodes (All, Non-Nocturnal, Nocturnal, and Severe)
percentage of participantsILPSGlargine
All Reported - Endpoint41.843.1
All Reported - Overall70.674.9
Non-Nocturnal - Endpoint30.640.1
Non-Nocturnal - Overall62.470.7
Nocturnal - Endpoint21.811.4
Nocturnal - Overall47.637.1
Severe - Endpoint00
Severe - Overall1.80
Statistical analysis
  • ILPS vs Glargine · Fisher Exact · p = 0.826 (p-value is for all reported hypoglycemic events at endpoint.)
  • ILPS vs Glargine · Fisher Exact · p = 0.394 (p-value is for all reported hypoglycemic events overall.)
  • ILPS vs Glargine · Fisher Exact · p = 0.070 (p-value is for non-nocturnal hypoglycemic events at endpoint.)
  • ILPS vs Glargine · Fisher Exact · p = 0.133 (p-value is for non-nocturnal hypoglycemic events overall.)
  • ILPS vs Glargine · Fisher Exact · p = 0.013 (p-value is for nocturnal hypoglycemic events at endpoint.)
  • ILPS vs Glargine · Fisher Exact · p = 0.061 (p-value is for nocturnal hypoglycemic events overall.)
  • ILPS vs Glargine · Fisher Exact · p = 0.248 (p-value is for severe hypoglycemic events overall.)
SecondaryRate of All, Non-Nocturnal, and Nocturnal Self-Reported Hypoglycemic Episodes (Adjusted for One Year)

Rate of self-reported hypoglycemic episodes, all, non-nocturnal, and nocturnal, at Endpoint (LOCF) and overall. Rate is reported as episodes/participant/365 days. Episode = any time participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia or has a blood glucose level of ≤70 mg/dL, even if it was not associated with signs, symptoms, or treatment. Overall=any time during the post-randomization visits within the study period. Nocturnal=Any episode that occurs between bedtime and waking. Non-Nocturnal=Any episode that occurs between waking and bedtime.

Time frame:
Baseline to Endpoint (LOCF) up to 24 weeks
Reported as:
Mean · episodes/participant/365 days
Rate of All, Non-Nocturnal, and Nocturnal Self-Reported Hypoglycemic Episodes (Adjusted for One Year)
episodes/participant/365 daysILPSGlargine
All reported episodes rate - Endpoint14.51 ± 27.7515.29 ± 29.73
All reported episodes rate - Overall16.27 ± 23.1918.05 ± 24.59
Non-Nocturnal reported episodes rate - Endpoint10.40 ± 23.4613.20 ± 28.01
Non-Nocturnal reported episodes rate - Overall11.36 ± 19.1614.83 ± 21.00
Nocturnal reported episodes rate - Endpoint4.01 ± 9.731.73 ± 5.53
Nocturnal reported episodes rate - Overall4.88 ± 8.433.01 ± 7.21
Statistical analysis
  • ILPS vs Glargine · Negative Binomial regression model · p = 0.628 (p-value is for All reported episodes rate - Endpoint.)Total hypoglycemia count=Treatment+Baseline HbA1c Group+Baseline SU Group with log of patient's total number of days of exposure as an offset variable
  • ILPS vs Glargine · Negative Binomial regression model · p = 0.570 (p-value is for All reported episodes rate - Overall.)Total hypoglycemia count=Treatment+Baseline HbA1c Group+Baseline SU Group with log of patient's total number of days of exposure as an offset variable
  • ILPS vs Glargine · Negative Binomial regression model · p = 0.116 (p-value is for Non-Nocturnal reported episodes rate - Endpoint.)Total hypoglycemia count=Treatment+Baseline HbA1c Group+Baseline SU Group with log of patient's total number of days of exposure as an offset variable
  • ILPS vs Glargine · Negative Binomial regression model · p = 0.044 (p-value is for Non-Nocturnal reported episodes rate - Overall.)Total hypoglycemia count=Treatment+Baseline HbA1c Group+Baseline SU Group with log of patient's total number of days of exposure as an offset variable
  • ILPS vs Glargine · Negative Binomial regression model · p = 0.006 (p-value is for Nocturnal reported episodes rate - Endpoint.)Total hypoglycemia count=Treatment+Baseline HbA1c Group+Baseline SU Group with log of patient's total number of days of exposure as an offset variable
  • ILPS vs Glargine · Negative Binomial regression model · p = 0.004 (p-value is for Nocturnal reported episodes rate - Overall.)Total hypoglycemia count=Treatment+Baseline HbA1c Group+Baseline SU Group with log of patient's total number of days of exposure as an offset variable
SecondaryActual Body Weight at Baseline and Endpoint (LOCF)
Time frame:
Baseline, Endpoint (LOCF) up to 24 weeks
Reported as:
Mean · kilograms
Actual Body Weight at Baseline and Endpoint (LOCF)
kilogramsILPSGlargine
Baseline101.57 ± 18.67102.62 ± 19.58
Endpoint101.85 ± 18.91103.28 ± 19.42
Statistical analysis
  • ILPS vs Glargine · ANCOVA · p = 0.343 (p-value is for endpoint.)Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group (Type III sums of squares)
SecondaryChange From Baseline in Body Weight at Endpoint (LOCF)
Time frame:
Baseline, Endpoint (LOCF) up to 24 weeks
Reported as:
Mean · kilograms
Change From Baseline in Body Weight at Endpoint (LOCF)
kilogramsILPSGlargine
Change From Baseline in Body Weight at Endpoint (LOCF)0.27 ± 3.380.66 ± 3.93
Statistical analysis
  • ILPS · t-test, 2 sided · p = 0.417 (p-value is for the change in body weight at endpoint in the ILPS treatment group.)
  • Glargine · t-test, 2 sided · p = 0.041 (p-value is for the change in body weight at endpoint in the glargine treatment group.)
  • ILPS vs Glargine · ANOVA · p = 0.343 (p-value is for change in body weight at endpoint between ILPS and glargine treatment groups.) · Mean difference (final values): -0.38 · 95% CI -1.15 to 0.40
SecondaryTotal Daily Insulin Dose at Endpoint (LOCF)
Time frame:
Endpoint (LOCF) up to 24 weeks
Reported as:
Mean · Units of Insulin
Total Daily Insulin Dose at Endpoint (LOCF)
Units of InsulinILPSGlargine
Total Daily Insulin Dose at Endpoint (LOCF)31.11 ± 18.8737.93 ± 18.46
Statistical analysis
  • ILPS vs Glargine · ANOVA · p = <0.001Variable = Treatment + Baseline HbA1c Group+ Baseline SU Group

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ILPS—9/170 (5.3%)96/170 (56.5%)
Glargine—5/167 (3%)115/167 (68.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventILPSGlargine
Atrial fibrillationCardiac disorders2/1700/167
Chest painGeneral disorders0/1701/167
CholelithiasisHepatobiliary disorders0/1701/167
Ankle fractureInjury, poisoning and procedural complications0/1701/167
Drug exposure during pregnancyInjury, poisoning and procedural complications0/1701/167
FallInjury, poisoning and procedural complications0/1701/167
Heat exhaustionInjury, poisoning and procedural complications0/1701/167
AppendicitisInfections and infestations1/1700/167
Cystitis bacterialInfections and infestations1/1700/167
Pneumonia pneumococcalInfections and infestations1/1700/167
Most frequent other events
Showing 10 of 25
Most frequent other events
EventILPSGlargine
HeadacheNervous system disorders11/17015/167
NauseaGastrointestinal disorders13/17010/167
DiarrhoeaGastrointestinal disorders11/17012/167
Gastroenteritis viralInfections and infestations2/17012/167
NasopharyngitisInfections and infestations12/1709/167
Upper respiratory tract infectionInfections and infestations11/17010/167
SinusitisInfections and infestations7/1709/167
Nasal congestionRespiratory, thoracic and mediastinal disorders3/1709/167
ArthralgiaMusculoskeletal and connective tissue disorders9/1707/167
VomitingGastrointestinal disorders6/1708/167

Baseline characteristics

Age Continuous
Age Continuous(years)ILPSGlargineTotal
Mean56.51 ± 9.7356.24 ± 9.3356.38 ± 9.52
Sex: Female, Male
Sex: Female, Male(Participants)ILPSGlargineTotal
Female9575170
Male7693169
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ILPSGlargineTotal
Black or African American131427
East Asian5611
Hispanic211738
Native American011
West Asian (Indian sub-continent)202
White130130260
Region of Enrollment
Region of Enrollment(participants)ILPSGlargineTotal
United States165165330
Puerto Rico639
Body Mass Index
Body Mass Index(kilograms/square meters (kg/m^2))ILPSGlargineTotal
Mean34.92 ± 5.2134.78 ± 5.1734.85 ± 5.18
Body Weight
Body Weight(Kilograms)ILPSGlargineTotal
Mean101.57 ± 18.67102.33 ± 19.73101.95 ± 19.18
Hemoglobin A1C
Hemoglobin A1C(percent of glycosylated hemoglobin)ILPSGlargineTotal
Mean8.21 ± 0.798.22 ± 0.808.22 ± 0.79
Sulfonylurea Group
Sulfonylurea Group(participants)ILPSGlargineTotal
Yes108110218
No6358121

1 further baseline measures are reported on the registry.

08

Study locations

52 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Phoenix, Arizona 85028, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Concord, California 94520, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Escondido, California 92026, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fresno, California 93720, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Modesto, California 95355, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orange, California 92869, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Inverness, Florida 34452, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32204, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lake Worth, Florida 33461, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33183, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32804, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palm Harbor, Florida 34684, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pembroke Pines, Florida 33029, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Plantation, Florida 33324, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Palm Beach, Florida 33401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Honolulu, Hawaii 96813, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Idaho Falls, Idaho 83404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Avon, Indiana 46123, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bloomington, Indiana 47403, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    South Bend, Indiana 46617, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Des Moines, Iowa 50314, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lexington, Kentucky 40503, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baton Rouge, Louisiana 70808, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lafayette, Louisiana 70503, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Metairie, Louisiana 70006, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Biddeford, Maine 04005, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chesterfield, Missouri 63017, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jefferson City, Missouri 65109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63104, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Omaha, Nebraska 68131, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Las Vegas, Nevada 89148, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashua, New Hampshire 03063, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rochester, New York 14607, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Syracuse, New York 13210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Morehead City, North Carolina 28557, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, Ohio 43140, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mason, Ohio 45040, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toledo, Ohio 43606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greer, South Carolina 29651, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Myrtle Beach, South Carolina 29572, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kingsport, Tennessee 37660, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38119, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78731, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75231, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    South Burlington, Vermont 05403, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Virginia Beach, Virginia 23462, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spokane, Washington 99202, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vancouver, Washington 98664, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ponce, 00731, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toa Baja, 00949, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yabucoa, 00767, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2007
First posted
Nov 19, 2007
Start
Nov 2007
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Dec 14, 2010
Last update
Jan 13, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00560417
First posted
Nov 19, 2007
Start date
Nov 2007
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Dec 14, 2010
Last update
Jan 13, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Lispro · Insulin Glargine

Start the discussion